FONDAZIONE ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO POLICLINICO SAN MATTEO;
Blood. 2014 Jan 16;123(3):305-7. doi: 10.1182/blood-2013-12-539940.
In this issue of Blood, Turesson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS) to lymphoplasmacellular and myeloid malignancies in a large population, validating current risk factors and adding immunoparesis as a predictor of progression.
在本期《Blood》中,Turesson 等人研究了在一个大人群中,意义未明的单克隆丙种球蛋白血症(MGUS)进展为淋巴浆细胞和髓系恶性肿瘤的风险,验证了当前的风险因素,并将免疫缺陷作为进展的预测因素。